Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
The survival of most patients with acute myelogenous leukemia (AML) remains poor, and novel therapeutic approaches are needed to improve outcomes. Given that the fraction of AML with mutated p53 is small ( approximately 10%), it appears rational to study MDM2 inhibitors as therapy for AML. Here, we report results of a detailed characterization of sensitivity and resistance to treatment ex vivo with the MDM2 inhibitor MI219 in AML blasts from 109 patients. In line with previous observations, all AML cases with mutated p53 were resistant to MI219. Importantly, approximately 30% of AML cases with unmutated p53 also demonstrated primary resistance to MI219. Analysis of potential mechanisms associated with MI219 resistance in AML blasts with wild-type p53 uncovered distinct molecular defects, including low or absent p53 protein induction after MDM2 inhibitor treatment or external irradiation. Furthermore, a separate subset of resistant blasts displayed robust p53 protein induction after MI219 treatment, indicative of defective p53 protein function or defects in the apoptotic p53 network. Finally, analysis of very sensitive AML cases uncovered a strong and significant association with mutated Flt3 status (Flt3-ITD), which for the first time identified a clinically high-risk group of AML that may particularly benefit from MDM2 inhibitor treatment.
Long
Jianting
J
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109-0936, USA.
Parkin
Brian
B
Ouillette
Peter
P
Bixby
Dale
D
Shedden
Kerby
K
Erba
Harry
H
Wang
Shaomeng
S
Malek
Sami N
SN
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis / Q000187:drug effects*; D018797:Cell Cycle Proteins; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D015151:Immunoblotting; D007211:Indoles / Q000494:pharmacology; D007951:Leukemia, Myeloid / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism; D051736:Proto-Oncogene Proteins c-mdm2 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013141:Spiro Compounds / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics / Q000378:metabolism
D018797:Cell Cycle Proteins; D007093:Imidazoles; D007211:Indoles; C482775:MDM4 protein, human; C543589:MI-63 compound; D009687:Nuclear Proteins; D010879:Piperazines; D011518:Proto-Oncogene Proteins; D013141:Spiro Compounds; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C482205:nutlin 3; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3099-104
11867746
Oncogene. 2008 Sep 11;27(40):5303-14
18521084
Leukemia. 2009 Apr;23(4):656-63
19151774
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10408-13
18641120
Blood. 2008 Feb 1;111(3):1584-93
17971485
Blood. 2008 Mar 1;111(5):2527-37
17965322
Clin Cancer Res. 2008 Sep 1;14(17):5318-24
18765522
Nature. 1997 May 15;387(6630):299-303
9153396
J Biol Chem. 2006 Nov 3;281(44):33030-5
16905541
Cell. 2003 Mar 21;112(6):779-91
12654245
Cell. 2005 Oct 7;123(1):49-63
16213212
EMBO J. 2006 Sep 6;25(17):4084-96
16946709
Blood. 2001 Jun 1;97(11):3589-95
11369655
Blood. 2005 Nov 1;106(9):3150-9
16014563
Cell Cycle. 2009 Jun 1;8(11):1711-9
19411846
Nat Rev Cancer. 2009 Oct;9(10):749-58
19776744
Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3232-7
16492744
Leukemia. 2008 Sep;22(9):1728-36
18548093
Leukemia. 2010 Jan;24(1):33-43
19946262
Blood. 2006 May 15;107(10):4109-14
16439685
Science. 1996 Nov 8;274(5289):948-53
8875929
Genes Dev. 2003 Sep 15;17(18):2233-8
12952892
Cell Cycle. 2009 Jan 1;8(1):31-4
19106616
Blood. 2006 Aug 1;108(3):993-1000
16543464
Science. 2004 Feb 6;303(5659):844-8
14704432
J Cell Biol. 2006 May 22;173(4):533-44
16717128
Blood. 2009 Apr 30;113(18):4300-8
19190243
J Med Chem. 2006 Jun 15;49(12):3432-5
16759082
Bioinformatics. 2004 May 22;20(8):1233-40
14871870
Cell. 2009 May 1;137(3):413-31
19410540
J Biol Chem. 2009 Sep 25;284(39):26315-21
19648117
Trends Mol Med. 2007 Jan;13(1):23-31
17126603
Nature. 2006 Nov 2;444(7115):61-6
17080083
Clin Cancer Res. 2007 Aug 15;13(16):4777-85
17699855
Mol Cell. 2008 Feb 1;29(2):217-31
18243116
Nat Rev Mol Cell Biol. 2008 Sep;9(9):702-12
18719709
Blood. 1991 Oct 1;78(7):1652-7
1912553
Mol Cell. 2008 Oct 24;32(2):180-9
18951086
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8
18316739
Am J Clin Pathol. 1993 Nov;100(5):534-40
8249893
Cell Cycle. 2009 Jun 1;8(11):1647-8
19448434
Science. 2003 Nov 7;302(5647):1036-8
14500851
Nature. 2004 May 6;429(6987):86-92
15103385
Nature. 1997 May 15;387(6630):296-9
9153395
Cancer Cell. 2009 Mar 3;15(3):171-83
19249676
Blood. 2005 Nov 15;106(10):3609-17
16081689
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93
16443686
Cell. 2009 May 15;137(4):609-22
19450511
Blood. 2006 May 15;107(10):4122-9
16439677